BACKGROUND: Apo (apolipoprotein) M mediates the physical interaction between high-density lipoprotein (HDL) particles and sphingosine-1-phosphate (S1P). Apo M exerts anti-inflammatory and cardioprotective effects in animal models. METHODS: In a subset of PHFS (Penn Heart Failure Study) participants (n=297), we measured apo M by Enzyme-Linked ImmunoSorbent Assay (ELISA). We also measured total S1P by liquid chromatography-mass spectrometry and isolated HDL particles to test the association between apo M and HDL-associated S1P. We confirmed the relationship between apo M and outcomes using modified aptamer-based apo M measurements among 2170 adults in the PHFS and 2 independent cohorts: the Washington University Heart Failure Registry (n=173) and a subset of TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial; n=218). Last, we examined the relationship between apo M and ≈5000 other proteins (SomaScan assay) to identify biological pathways associated with apo M in heart failure. RESULTS: In the PHFS, apo M was inversely associated with the risk of death (standardized hazard ratio, 0.56 [95% CI, 0.51-0.61]; P<0.0001) and the composite of death/ventricular assist device implantation/heart transplantation (standardized hazard ratio, 0.62 [95% CI, 0.58-0.67]; P<0.0001). This relationship was independent of HDL cholesterol or apo AI levels. Apo M remained associated with death (hazard ratio, 0.78 [95% CI, 0.69-0.88]; P<0.0001) and the composite of death/ventricular assist device/heart transplantation (hazard ratio, 0.85 [95% CI, 0.76-0.94]; P=0.001) in models that adjusted for multiple confounders. This association was present in both heart failure with reduced and preserved ejection fraction and was replicated in the Washington University cohort and a cohort with heart failure with preserved ejection fraction only (TOPCAT). The S1P and apo M content of isolated HDL particles strongly correlated (R=0.81, P<0.0001). The top canonical pathways associated with apo M were inflammation (negative association), the coagulation system (negative association), and liver X receptor/retinoid X receptor activation (positive association). The relationship with inflammation was validated with multiple inflammatory markers measured with independent assays. CONCLUSIONS: Reduced circulating apo M is independently associated with adverse outcomes across the spectrum of human heart failure. Further research is needed to assess whether the apo M/S1P axis is a suitable therapeutic target in heart failure.
BACKGROUND: Apo (apolipoprotein) M mediates the physical interaction between high-density lipoprotein (HDL) particles and sphingosine-1-phosphate (S1P). Apo M exerts anti-inflammatory and cardioprotective effects in animal models. METHODS: In a subset of PHFS (Penn Heart Failure Study) participants (n=297), we measured apo M by Enzyme-Linked ImmunoSorbent Assay (ELISA). We also measured total S1P by liquid chromatography-mass spectrometry and isolated HDL particles to test the association between apo M and HDL-associated S1P. We confirmed the relationship between apo M and outcomes using modified aptamer-based apo M measurements among 2170 adults in the PHFS and 2 independent cohorts: the Washington University Heart Failure Registry (n=173) and a subset of TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial; n=218). Last, we examined the relationship between apo M and ≈5000 other proteins (SomaScan assay) to identify biological pathways associated with apo M in heart failure. RESULTS: In the PHFS, apo M was inversely associated with the risk of death (standardized hazard ratio, 0.56 [95% CI, 0.51-0.61]; P<0.0001) and the composite of death/ventricular assist device implantation/heart transplantation (standardized hazard ratio, 0.62 [95% CI, 0.58-0.67]; P<0.0001). This relationship was independent of HDL cholesterol or apo AI levels. Apo M remained associated with death (hazard ratio, 0.78 [95% CI, 0.69-0.88]; P<0.0001) and the composite of death/ventricular assist device/heart transplantation (hazard ratio, 0.85 [95% CI, 0.76-0.94]; P=0.001) in models that adjusted for multiple confounders. This association was present in both heart failure with reduced and preserved ejection fraction and was replicated in the Washington University cohort and a cohort with heart failure with preserved ejection fraction only (TOPCAT). The S1P and apo M content of isolated HDL particles strongly correlated (R=0.81, P<0.0001). The top canonical pathways associated with apo M were inflammation (negative association), the coagulation system (negative association), and liver X receptor/retinoid X receptor activation (positive association). The relationship with inflammation was validated with multiple inflammatory markers measured with independent assays. CONCLUSIONS: Reduced circulating apo M is independently associated with adverse outcomes across the spectrum of humanheart failure. Further research is needed to assess whether the apo M/S1P axis is a suitable therapeutic target in heart failure.
Entities:
Keywords:
apolipoproteins M; heart failure; lipoproteins, HDL; sphingosine-1-phosphate; survival
Authors: Edward Brody; Larry Gold; Mike Mehan; Rachel Ostroff; John Rohloff; Jeff Walker; Dom Zichi Journal: J Mol Biol Date: 2012-06-19 Impact factor: 5.469
Authors: Peter Ganz; Bettina Heidecker; Kristian Hveem; Christian Jonasson; Shintaro Kato; Mark R Segal; David G Sterling; Stephen A Williams Journal: JAMA Date: 2016-06-21 Impact factor: 56.272
Authors: Akshay S Desai; Eldrin F Lewis; Rebecca Li; Scott D Solomon; Susan F Assmann; Robin Boineau; Nadine Clausell; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Sonja McKinlay; Eileen O'Meara; Tamaz Shaburishvili; Bertram Pitt; Marc A Pfeffer Journal: Am Heart J Date: 2011-11-08 Impact factor: 4.749
Authors: Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245
Authors: Carolyn S P Lam; Greg D Gamble; Lieng H Ling; David Sim; Kui Toh Gerard Leong; Poh Shuan Daniel Yeo; Hean Yee Ong; Fazlur Jaufeerally; Tze P Ng; Vicky A Cameron; Katrina Poppe; Mayanna Lund; Gerry Devlin; Richard Troughton; A Mark Richards; Robert N Doughty Journal: Eur Heart J Date: 2018-05-21 Impact factor: 29.983
Authors: Kirsi Auro; Anni Joensuu; Krista Fischer; Johannes Kettunen; Perttu Salo; Hannele Mattsson; Marjo Niironen; Jaakko Kaprio; Johan G Eriksson; Terho Lehtimäki; Olli Raitakari; Antti Jula; Aila Tiitinen; Matti Jauhiainen; Pasi Soininen; Antti J Kangas; Mika Kähönen; Aki S Havulinna; Mika Ala-Korpela; Veikko Salomaa; Andres Metspalu; Markus Perola Journal: Nat Commun Date: 2014-08-21 Impact factor: 14.919
Authors: Larry Gold; Deborah Ayers; Jennifer Bertino; Christopher Bock; Ashley Bock; Edward N Brody; Jeff Carter; Andrew B Dalby; Bruce E Eaton; Tim Fitzwater; Dylan Flather; Ashley Forbes; Trudi Foreman; Cate Fowler; Bharat Gawande; Meredith Goss; Magda Gunn; Shashi Gupta; Dennis Halladay; Jim Heil; Joe Heilig; Brian Hicke; Gregory Husar; Nebojsa Janjic; Thale Jarvis; Susan Jennings; Evaldas Katilius; Tracy R Keeney; Nancy Kim; Tad H Koch; Stephan Kraemer; Luke Kroiss; Ngan Le; Daniel Levine; Wes Lindsey; Bridget Lollo; Wes Mayfield; Mike Mehan; Robert Mehler; Sally K Nelson; Michele Nelson; Dan Nieuwlandt; Malti Nikrad; Urs Ochsner; Rachel M Ostroff; Matt Otis; Thomas Parker; Steve Pietrasiewicz; Daniel I Resnicow; John Rohloff; Glenn Sanders; Sarah Sattin; Daniel Schneider; Britta Singer; Martin Stanton; Alana Sterkel; Alex Stewart; Suzanne Stratford; Jonathan D Vaught; Mike Vrkljan; Jeffrey J Walker; Mike Watrobka; Sheela Waugh; Allison Weiss; Sheri K Wilcox; Alexey Wolfson; Steven K Wolk; Chi Zhang; Dom Zichi Journal: PLoS One Date: 2010-12-07 Impact factor: 3.240
Authors: Victoria A Blaho; Sylvain Galvani; Eric Engelbrecht; Catherine Liu; Steven L Swendeman; Mari Kono; Richard L Proia; Lawrence Steinman; May H Han; Timothy Hla Journal: Nature Date: 2015-06-08 Impact factor: 49.962
Authors: Luigi Adamo; Jinsheng Yu; Cibele Rocha-Resende; Ali Javaheri; Richard D Head; Douglas L Mann Journal: J Am Coll Cardiol Date: 2020-10-27 Impact factor: 24.094
Authors: Hongsheng Gui; Ruicong She; Jasmine Luzum; Jia Li; Timothy D Bryson; Yigal Pinto; Hani N Sabbah; L Keoki Williams; David E Lanfear Journal: Circ Genom Precis Med Date: 2021-05-17
Authors: Thomas C Hanff; Jordana B Cohen; Lei Zhao; Ali Javaheri; Payman Zamani; Stuart B Prenner; Ernst Rietzschel; Yi Jia; Alice Walsh; Joseph Maranville; Zhaoqing Wang; Leonard Adam; Francisco Ramirez-Valle; Peter Schafer; Dietmar Seiffert; David A Gordon; Mary E Cvijic; Thomas P Cappola; Julio A Chirinos Journal: JACC Basic Transl Sci Date: 2021-02-10
Authors: Daniel H Katz; Jeremy M Robbins; Shuliang Deng; Usman A Tahir; Alexander G Bick; Akhil Pampana; Zhi Yu; Debby Ngo; Mark D Benson; Zsu-Zsu Chen; Daniel E Cruz; Dongxiao Shen; Yan Gao; Claude Bouchard; Mark A Sarzynski; Adolfo Correa; Pradeep Natarajan; James G Wilson; Robert E Gerszten Journal: Sci Adv Date: 2022-08-19 Impact factor: 14.957
Authors: María Concepción Izquierdo; Niroshan Shanmugarajah; Samuel X Lee; Michael J Kraakman; Marit Westerterp; Takumi Kitamoto; Michael Harris; Joshua R Cook; Galina A Gusarova; Kendra Zhong; Elijah Marbuary; InSug O-Sullivan; Nikolaus Rasmus; Stefania Camastra; Terry G Unterman; Ele Ferrannini; Barry E Hurwitz; Rebecca A Haeusler Journal: J Clin Invest Date: 2022-04-01 Impact factor: 19.456